Tirzepatide Causes Significant Weight Loss in Type 2 Diabetes (SURMOUNT-2).

Published Date: 27 Jun 2023

In the pivotal SURMOUNT-2 trial, weekly tirzepatide injections safely resulted in weight losses of 12 point 8 to 14 point 7 percent in adults with type 2 diabetes who were overweight or obese after 72 weeks.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Newly identified T-cell subtype may explain treatment-resistant childhood leukemia

2.

Glioblastoma treatment breakthrough shows promise

3.

A computer-aided diagnostic system for improved detection of breast cancer.

4.

Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy

5.

Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot